Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
Antibodies, Monoclonal
BA.2 subvariant
COVID-19
COVID-19 drug treatment
Omicron
SARS-CoV-2
Sotrovimab
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
received:
20
08
2023
accepted:
16
01
2024
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
24
1
2024
Statut:
epublish
Résumé
In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2. A multicentre, retrospective cohort study was conducted at three Canadian academic tertiary centres. Electronic medical records were reviewed for patients ≥ 18 years with mild COVID-19 (sequencing-confirmed Omicron BA.1 or BA.2) treated with sotrovimab between February 1 to April 1, 2022. Thirty-day co-primary outcomes included hospitalization due to moderate or severe COVID-19; all-cause intensive care unit (ICU) admission, and all-cause mortality. Risk differences (BA.2 minus BA.1 group) for co-primary outcomes were adjusted with propensity score matching (e.g., age, sex, vaccination, immunocompromised status). Eighty-five patients were included (15 BA.2, 70 BA.1) with similar baseline characteristics between groups. Adjusted risk differences were non-statistically significant between groups for 30-day hospitalization (- 14.3%; 95% confidence interval (CI): - 32.6 to 4.0%), ICU admission (- 7.1%; 95%CI: - 20.6 to 6.3%), and mortality (- 7.1%; 95%CI: - 20.6 to 6.3%). No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab's effectiveness against infections due to specific emerging COVID-19 variants.
Sections du résumé
BACKGROUND
BACKGROUND
In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2.
METHODS
METHODS
A multicentre, retrospective cohort study was conducted at three Canadian academic tertiary centres. Electronic medical records were reviewed for patients ≥ 18 years with mild COVID-19 (sequencing-confirmed Omicron BA.1 or BA.2) treated with sotrovimab between February 1 to April 1, 2022. Thirty-day co-primary outcomes included hospitalization due to moderate or severe COVID-19; all-cause intensive care unit (ICU) admission, and all-cause mortality. Risk differences (BA.2 minus BA.1 group) for co-primary outcomes were adjusted with propensity score matching (e.g., age, sex, vaccination, immunocompromised status).
RESULTS
RESULTS
Eighty-five patients were included (15 BA.2, 70 BA.1) with similar baseline characteristics between groups. Adjusted risk differences were non-statistically significant between groups for 30-day hospitalization (- 14.3%; 95% confidence interval (CI): - 32.6 to 4.0%), ICU admission (- 7.1%; 95%CI: - 20.6 to 6.3%), and mortality (- 7.1%; 95%CI: - 20.6 to 6.3%).
CONCLUSIONS
CONCLUSIONS
No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab's effectiveness against infections due to specific emerging COVID-19 variants.
Identifiants
pubmed: 38267971
doi: 10.1186/s13104-024-06695-x
pii: 10.1186/s13104-024-06695-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Informations de copyright
© 2024. The Author(s).
Références
Siemieniuk RA, Bartoszko JJ, Zeraatkar D, Kum E, Qasim A, Martinez JPD, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. https://doi.org/10.1136/bmj.m2980 .
doi: 10.1136/bmj.m2980
pubmed: 32732190
Hernandez AV, Piscoya A, Pasupuleti V, Phan MT, Julakanti S, Khen P, et al. Beneficial and harmful effects of monoclonal antibodies for the treatment and prophylaxis of COVID-19: systematic review and meta-analysis. Am J Med. 2022;135(11):1349-61.e18. https://doi.org/10.1016/j.amjmed.2022.06.019 .
doi: 10.1016/j.amjmed.2022.06.019
pubmed: 35878688
pmcid: 9307485
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med. 2022;386(15):1475–7. https://doi.org/10.1056/nejmc2201933 .
doi: 10.1056/nejmc2201933
pubmed: 35263535
Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group. Clinical practice guideline summary: recommended drugs and biologics in adult patients with COVID-19 (version 10.0). Ontario COVID-19 Science Advisory Table. 2022. https://doi.org/10.47326/ocsat.cpg.2022.10.0 . Accessed 7 June 2023.
Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 Omicron variant sub-lineage BA.2: evidence and risk assessment (up to date as of March 22, 2022). Queen's Printer for Ontario. 2022. https://www.publichealthontario.ca/-/media/Documents/nCoV/voc/2022/03/omicron-variant-ba2-risk-assessment-mar-22.ashx?la=fr . Accessed 27 May 2023.
U.S. Food and Drug Administration. FDA updates Sotrovimab emergency use authorization. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization . Updated Apr 5, 2022. Accessed 12 Apr 2023.
Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group. Clinical practice guideline summary: recommended drugs and biologics in adult patients with COVID-19 (version 11.0). Ontario COVID-19 Science Advisory Table. 2022. https://doi.org/10.47326/ocsat.cpg.2022.11.0 . Accessed 7 June 2023.
Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J, et al. Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England. Influenza Other Respir Viruses. 2023;17(5):e13150. https://doi.org/10.1111/irv.13150 .
doi: 10.1111/irv.13150
pubmed: 37246147
pmcid: 10225304
Martin-Blondel G, Marcelin A-G, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, et al. Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. J Infect. 2022;85(4):e104–8. https://doi.org/10.1016/j.jinf.2022.06.033 .
doi: 10.1016/j.jinf.2022.06.033
pubmed: 35803386
pmcid: 9254651
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, et al. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. Clin Microbiol Infect. 2023;29(4):543.e5-e9. https://doi.org/10.1016/j.cmi.2022.12.016 .
doi: 10.1016/j.cmi.2022.12.016
pubmed: 36586513
World Health Organization. Therapeutics and COVID-19: living guideline, 13 January 2023. World Health Organization. 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1 . Accessed 7 June 2023.
Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat. 2000;54(4):280–8. https://doi.org/10.2307/2685779 .
doi: 10.2307/2685779
Agresti A, Min Y. Effects and non-effects of paired identical observations in comparing proportions with binary matched-pairs data. Stat Med. 2004;23(1):65–75. https://doi.org/10.1002/sim.1589 .
doi: 10.1002/sim.1589
pubmed: 14695640
Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010;29(20):2137–48. https://doi.org/10.1002/sim.3854 .
doi: 10.1002/sim.3854
pubmed: 20108233
pmcid: 3068290
Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28. https://doi.org/10.18637/jss.v042.i08 .
doi: 10.18637/jss.v042.i08
Signorell A, Aho K, Alfons A, Anderegg N, Aragon T, Arachchige C, et al. DescTools: tools for descriptive statistics. R package, version 2021:0.99.40. https://cran.r-project.org/web/packages/DescTools/index.html . Updated Feb 3, 2021. Accessed 19 Aug 2023.
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, et al. Effect of Sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–46. https://doi.org/10.1001/jama.2022.2832 .
doi: 10.1001/jama.2022.2832
pubmed: 35285853
pmcid: 8922199